Metformin Plus MitoQ Combo Reverses Gulf War Illness Symptoms in Mice

Gulf War Illness (GWI) affects approximately one-third of Persian Gulf War veterans, causing persistent symptoms including chronic fatigue, muscle pain, neurological problems, and cognitive impairment that have persisted for over 30 years without effective treatments. This study investigated whether targeting mitochondrial dysfunction—a suspected core mechanism in GWI—could provide therapeutic benefit.

Researchers used an established mouse model where C57BL/6 mice were exposed to pyridostigmine bromide (0.7 mg/kg) and permethrin (200 mg/kg) daily for 10 days to simulate Gulf War chemical exposures. After an 8-month latency period mimicking the delayed onset of human GWI, mice received 8 weeks of treatment with metformin (50 mg/kg), MitoQ (400 μg/kg), both drugs combined, or vehicle control via oral gavage every other day.

The combination therapy produced the most robust improvements across multiple measures. In behavioral tests, treated mice showed significantly improved performance on the hanging wire test (measuring muscle strength), rotarod test (coordination and endurance), and voluntary wheel running activity compared to untreated GWI mice (p<0.05-0.01). At the molecular level, combination treatment activated AMPK signaling more effectively than individual treatments, reduced oxidative stress markers including malondialdehyde levels, and decreased inflammatory markers like myeloperoxidase activity by approximately 34% versus controls.

Mitochondrial function analysis revealed that the combination therapy rescued cellular respiration capacity and improved ATP production in gastrocnemius muscle tissue. The treatment also restored autophagy pathways (cellular cleanup mechanisms) that were impaired in the GWI model, as evidenced by normalized LC3B and p62 protein levels. Additionally, the therapy reduced tissue inflammation and improved antioxidant defenses through Nrf2 pathway activation.

These findings suggest that dual targeting of mitochondrial dysfunction through metabolic activation (metformin) and antioxidant protection (MitoQ) could address the underlying energetic and inflammatory pathways driving GWI symptoms. Both compounds are already available—metformin as an FDA-approved diabetes medication and MitoQ as a dietary supplement—potentially enabling rapid translation to human trials for the estimated 175,000+ veterans still suffering from GWI.